Effectiveness of Natalizumab in Achieving No Evidence of Disease Activity (NEDA-3)—Data From a Local Norwegian Cohort

Effectiveness of Natalizumab in Achieving No Evidence of Disease Activity (NEDA-3)—Data From a Local Norwegian Cohort

Objective: We aimed to determine the effectiveness of natalizumab (NTZ) by assessing overall No Evidence of Disease Activity 3 (NEDA-3) in a local Norwegian cohort.Background: NTZ is an immunomodulating drug used in the treatment of multiple sclerosis (MS). It has typically been used as a second-lin...

Full description

Bibliographic Details
Main Authors: Andreas K. Jaklin, Espen Benjaminsen, Karl B. Alstadhaug
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-10-01
Series:Frontiers in Neurology
Subjects:
multiple sclerosis
natalizumab
NEDA
JCV
effectiveness
survival analysis
Online Access:https://www.frontiersin.org/articles/10.3389/fneur.2021.765837/full

Similar Items

Similar Items